{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:15:16Z","timestamp":1789168516076,"version":"build-2803163510"},"reference-count":12,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Temporal trends of metastatic prostate cancer (mPCa) in the prostate\u2010specific membrane antigen positron emission tomography (PSMA PET) era in the United States are not known.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the Surveillance, Epidemiology, and End Results (SEER) database (2018\u20132022), all PCa patients were identified. Estimated annual percentage change (EAPC) and multivariable logistic regression (MLR) models tested the effect of the PSMA PET era (2021\u20132022) on mPCa rate and its substages\u00a0(M1a, M1b, M1c) rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 236,723 PCa patients were identified. Of those, 20,450 (8.6%) harbored mPCa. mPCa rate increased from 7.9% in 2018 to 9.4% in 2022 (EAPC: +4.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019). In MLR model, PSMA PET era independently predicted 1.1\u2010fold (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) increase in mPCa. Within mPCa patients, 1,564 (8.0%), 14,806 (72.0%), and 4,080 (20.0%) harbored M1a, M1b, and M1c substages. M1a and M1b substages rates increased in PSMA PET era (M1a: from 6.3% in 2018 to 9.1% in 2022, EAPC: +9.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009; M1b: from 70.3% in 2018 to 74.7% in 2022, EAPC: +1.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.043), but not M1c (from 23.3% in 2018 to 16.2% in 2022, EAPC: \u22128.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.036). In MLR models, PSMA PET era independently predicted 1.3\u2010fold increase (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) in M1a, 1.2\u2010fold increase (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) in M1b, but 0.7\u2010fold (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) decrease in M1c.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The introduction of PSMA PET resulted in an increase in the proportion of mPCa patients in the United States. Within those, M1a and M1b substages increased, but M1c decreased. These observations suggest a stage migration phenomenon, where low burden mPCa (M1a and M1b) is diagnosed more frequently at the expense of high burden mPCa (M1c).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pros.70212","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:38:32Z","timestamp":1783017512000},"page":"1316-1321","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temporal Trends of Metastatic Prostate Cancer in the Prostate\u2010Specific Membrane Antigen Positron Emission Tomography Era in the United States"],"prefix":"10.1002","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9523-3400","authenticated-orcid":false,"given":"Leonardo","family":"Quarta","sequence":"first","affiliation":[{"name":"Cancer Prognostics and Health Outcomes Unit University of Montr\u00e9al Health Center, Division of Urology Montr\u00e9al Qu\u00e9bec Canada"},{"name":"Division of Experimental Oncology\/Unit of Urology, URI, Urological Research Institute IRCCS San Raffaele Scientific Institute Milan Italy"},{"name":"Vita\u2010Salute San Raffaele University Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5715-9965","authenticated-orcid":false,"given":"Maximilian","family":"Filzmayer","sequence":"additional","affiliation":[{"name":"Cancer Prognostics and Health Outcomes Unit University of Montr\u00e9al Health Center, Division of Urology Montr\u00e9al Qu\u00e9bec Canada"},{"name":"Department of Urology, University Hospital Goethe University Frankfurt Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Petix","sequence":"additional","affiliation":[{"name":"Cancer Prognostics and Health Outcomes Unit University of Montr\u00e9al Health Center, Division of Urology Montr\u00e9al Qu\u00e9bec Canada"},{"name":"Department of Urology ASST Santi Paolo e Carlo Milan Italy"},{"name":"Universit\u00e0 degli Studi di Milano Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Orlandi","sequence":"additional","affiliation":[{"name":"Cancer Prognostics and Health Outcomes Unit University of Montr\u00e9al Health Center, Division of Urology Montr\u00e9al Qu\u00e9bec Canada"},{"name":"Department of Urology, AOU di Modena University of Modena and Reggio Emilia Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4609-8981","authenticated-orcid":false,"given":"Jordan A.","family":"Goyal","sequence":"additional","affiliation":[{"name":"Cancer Prognostics and Health Outcomes Unit University of Montr\u00e9al Health Center, Division of Urology Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K. H.","family":"Chun","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Goethe University Frankfurt Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Ferro","sequence":"additional","affiliation":[{"name":"Department of Urology ASST Santi Paolo e Carlo Milan Italy"},{"name":"Universit\u00e0 degli Studi di Milano Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Micali","sequence":"additional","affiliation":[{"name":"Department of Urology, AOU di Modena University of Modena and Reggio Emilia Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[{"name":"Department of Urology, Comprehensive Cancer Center Medical University of Vienna Vienna Austria"},{"name":"Department of Urology Weill Cornell Medical College New York New York USA"},{"name":"Department of Urology University of Texas Southwestern Medical Center Dallas Texas USA"},{"name":"Hourani Center for Applied Scientific Research Al\u2010Ahliyya Amman University Amman Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3585-3217","authenticated-orcid":false,"given":"Francesco","family":"Barletta","sequence":"additional","affiliation":[{"name":"Division of Experimental Oncology\/Unit of Urology, URI, Urological Research Institute IRCCS San Raffaele Scientific Institute Milan Italy"},{"name":"Vita\u2010Salute San Raffaele University Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Stabile","sequence":"additional","affiliation":[{"name":"Division of Experimental Oncology\/Unit of Urology, URI, Urological Research Institute IRCCS San Raffaele Scientific Institute Milan Italy"},{"name":"Vita\u2010Salute San Raffaele University Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[{"name":"Division of Experimental Oncology\/Unit of Urology, URI, Urological Research Institute IRCCS San Raffaele Scientific Institute Milan Italy"},{"name":"Vita\u2010Salute San Raffaele University Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[{"name":"Division of Experimental Oncology\/Unit of Urology, URI, Urological Research Institute IRCCS San Raffaele Scientific Institute Milan Italy"},{"name":"Vita\u2010Salute San Raffaele University Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[{"name":"Cancer Prognostics and Health Outcomes Unit University of Montr\u00e9al Health Center, Division of Urology Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[{"name":"Division of Experimental Oncology\/Unit of Urology, URI, Urological Research Institute IRCCS San Raffaele Scientific Institute Milan Italy"},{"name":"Vita\u2010Salute San Raffaele University Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[{"name":"Cancer Prognostics and Health Outcomes Unit University of Montr\u00e9al Health Center, Division of Urology Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"crossref","unstructured":"\u201cThe FDA Approves PSMA Targeted Drug for PET Imaging in Men With Prostate Cancer \u201dBJU International127 no. 3 (2021): 267\u2013268 https:\/\/doi.org\/10.1111\/bju.15361.","DOI":"10.1111\/bju.15361"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.08.005"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.03.003"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.08.001"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.04.005"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.08.005"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268441"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000001916"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.027"},{"key":"e_1_2_12_12_1","unstructured":"National Comprehensive Cancer Network Inc. NCCN Guidelines Version 1.2024 Prostate Cancer(National Comprehensive Cancer Network Inc. 2024)."},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07431-8"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.70212","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pros.70212","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.70212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:42:42Z","timestamp":1789166562000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.70212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":12,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/pros.70212"],"URL":"https:\/\/doi.org\/10.1002\/pros.70212","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"2026-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}